BLSM

14.5100.69%
GO

Geoff Oxnard

Chief Medical Officer & Executive VP

Dr. Geoff Oxnard, M.D., is Chief Medical Officer & Executive VP of BlossomHill Therapeutics, Inc. from January 2025. Dr. Oxnard is a globally recognized clinical and translational cancer investigator who spent on faculty at the Dana-Farber Cancer Institute and Harvard Medical School from 2011 to 2020. His research catalyzed many of the early clinical insights into sensitivity and resistance to EGFR inhibitors in advanced lung cancer, including the first description of the EGFR C797S resistance mutation, reported in Nature Medicine in 2015. Dr. Oxnard's career as a clinical investigator and translational scientist has spanned across industry and academia with an aim toward delivering precision cancer therapies and better patient outcomes. His research focused on molecular drivers of sensitivity and resistance to precision cancer therapies and the application of molecular diagnostics to advance cancer care and drug development. He has authored over 200 scientific publications spanning a wide range of cancer science, from genomic discovery through registrational clinical trials. Dr. Oxnard also has had a medical practice since April 2021, serving as a part-time thoracic oncologist at Boston Medical Center, a safety-net hospital in Boston. Prior to joining BlossomHill Therapeutics, Inc., Dr. Oxnard served as Vice President, Global Head of Thoracic Cancers at Eli Lilly & Co. (formerly Loxo Oncology) from September 2023 through January 2025, where he accelerated the early and late-phase development of a diverse thoracic portfolio. From April 2021 to September 2023, Dr. Oxnard served as Senior Vice President, Head of Clinical Development at Foundation Medicine, a F. Hoffmann-La Roche AG company, where he supported the FDA approval of FoundationOne®Liquid CDx and the launch of an emerging ctDNA monitoring portfolio. Dr. Oxnard received his B.A. in chemistry from Harvard University and his M.D. from the University of Chicago-Pritzker School of Medicine. He completed his residency in internal medicine at Massachusetts General Hospital and completed a fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center in New York City.

Positions